Tirupati Sarjan is a real estate developer and civil construction firm that builds residential and commercial properties for middle-class buyers and executes government infrastructure projects like hospitals, roads, and educational campuses.
The company operates in a highly fragmented and competitive construction market with no clear cost advantage or brand power, evidenced by low net margins of 3% and a return on equity of 6.8% which barely covers the cost of capital.
Earnings are largely reinvested into working capital and land advances, but the returns on these investments are mediocre. A significant portion of capital is tied up in a non-performing Ugandan subsidiary and related-party land advances that have not yielded timely returns.
The investment collapsed as the company's chronic governance lapses and poor capital allocation finally hit a breaking point. The capital tied up in the non-performing Ugandan subsidiary was never recovered, and the significant advances to related parties for land procurement turned out to be a permanent drain on liquidity rather than productive assets. As the thin 3% margins were squeezed by rising input costs, the lack of independent board oversight allowed management to continue throwing good money after bad, leading to a liquidity crunch and a sharp devaluation of the equity as the market realized the 'cheap' book value was comprised of non-productive and inaccessible assets.
RichFakir rates Tirupati Sarjan Ltd's business quality as poor — 28/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Tirupati Sarjan Ltd is trading about 63% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Tirupati Sarjan Ltd is: Not rated. A poor business at a cheap price — it does not make our shortlist right now.
RichFakir's educational estimate of Tirupati Sarjan Ltd's fair value is about ₹19 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →